EUVIMEDEUVIMED entdecken
BeobachtungsstudieQuerschnittstudieOpen Access · CC BY-NC-ND 4.0

Differences in pharmacological migraine treatment across different levels of clinical headache care – a cross-sectional study

Mira Pauline Fitzek, Lucas Hendrik Overeem, Marlene Ulrich, Ja Bin Hong, Carolin Luisa Hoehne, Kristin Sophie Lange, Yones Salim, Uwe Reuter, Bianca Raffaelli

The Journal of Headache and Pain · 2025

DOI: 10.1186/s10194-025-02027-x ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift The Journal of Headache and Pain, 2025. Verfasst von Mira Pauline Fitzek und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Charité Universitätsmedizin Berlin, Charitéplatz 1, Berlin, 10117, Germany. mira.fitzek@charite.de. Hauptthemen laut MEDLINE: Analgesics, Migraine Disorders. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Migraine significantly impairs quality of life, reduces workplace productivity, and imposes a substantial socio-economic burden. The severity of migraine correlates with its impact on quality of life and healthcare costs, emphasizing the need for adequate management. In the past, primary care services often faced issues of inadequate treatment. This study evaluates differences in pharmacological recommendations for acute and preventive migraine treatments across primary, secondary, and tertiary care settings. METHODS: This cross-sectional study involves patients with confirmed migraine (with or without aura) visiting the tertiary headache center at Charité Berlin between 12/2015 and 01/2023 for the first time. Data on headache characteristics and prior treatments for acute and prophylactic treatments at primary/secondary and recommendations from tertiary level of care were retrieved from medical letters written after first consultation. RESULTS: Among 1,047 migraine patients (42 years, 84% women), 99% had received treatment for acute migraine attacks by primary/secondary care facilities, and 96% were using it at their first consultation, with 63% advised to use a triptan. The average number of triptans tested prior to referral was 1 ± 0.99. Prophylactic treatment was prescribed to 52% of patients by primary/secondary care facilities, with an average of 1.2 ± 1.6 prior prophylactic attempts per patient, and 44% were actively using it at the time of consultation. More than two thirds of patients with over four monthly migraine days were not using prophylactic treatment at referral. Tricyclic antidepressants, beta-blocker and, anticonvulsants were prescribed significantly more often in primary/secondary care settings while Onabotulinumtoxin-A and Calcitonin Gene-Related Peptide(-receptor) antibodies were more commonly initiated in tertiary care. Treatment recommendations from primary/secondary settings were revised in 77% of patients following consultation at the tertiary headache clinic. CONCLUSION: Compared to previous studies, the overall prescription of acute and prophylactic therapies in primary and secondary care facilities has improved. Further progress is needed in expanding the range of triptans and prophylactic treatments tested before referring patients to specialized centers. However, given the selected study population, the findings may not be fully applicable to all patients treated in primary/secondary care, especially those already receiving adequate care without being referred to specialized settings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnalgesicsMigraine DisordersAdultFemaleHumansMaleMiddle AgedCross-Sectional StudiesPrimary Health CareSecondary Health CareTryptamines

Stichwörter der Autor:innen

CGRPGeneral practitionersTreatment recommendationTriptans

Substanzen

AnalgesicsTryptamines

Autor:innen und Institutionen

  • Department of Neurology, Charité Universitätsmedizin Berlin, Charitéplatz 1, Berlin, 10117, Germany. mira.fitzek@charite.de.
  • Junior Clinician Scientist Program, Berlin Institute of Health (BIH), Berlin, Germany. mira.fitzek@charite.de.
  • Department of Neurology, Charité Universitätsmedizin Berlin, Charitéplatz 1, Berlin, 10117, Germany.
  • International Graduate Program Medical Neurosciences, Charité Universitätsmedizin Berlin, Berlin, Germany.
  • Clinician Scientist Program, Berlin Institute of Health (BIH), Berlin, Germany.
  • Universitätsmedizin Greifswald, Greifswald, Germany.

Zitieren

APA

Fitzek, M. P., Overeem, L. H., Ulrich, M., Hong, J. B., Hoehne, C. L., Lange, K. S., Salim, Y., Reuter, U., & Raffaelli, B. (2025). Differences in pharmacological migraine treatment across different levels of clinical headache care – a cross-sectional study. The Journal of Headache and Pain. https://doi.org/10.1186/s10194-025-02027-x

Vancouver

Fitzek MP, Overeem LH, Ulrich M, Hong JB, Hoehne CL, Lange KS, et al. Differences in pharmacological migraine treatment across different levels of clinical headache care – a cross-sectional study. The Journal of Headache and Pain. 2025. doi:10.1186/s10194-025-02027-x

BibTeX
@article{Fitzek2025,
  author = {Fitzek, Mira Pauline and Overeem, Lucas Hendrik and Ulrich, Marlene and Hong, Ja Bin and Hoehne, Carolin Luisa and Lange, Kristin Sophie and Salim, Yones and Reuter, Uwe and Raffaelli, Bianca},
  title = {Differences in pharmacological migraine treatment across different levels of clinical headache care – a cross-sectional study},
  journal = {The Journal of Headache and Pain},
  year = {2025},
  doi = {10.1186/s10194-025-02027-x}
}
Kostenlos starten →